These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 27177860)

  • 21. Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.
    Zhao Q; Hughes R; Neupane B; Mickle K; Su Y; Chabot I; Betts M; Kadambi A
    BMC Cancer; 2021 Jun; 21(1):758. PubMed ID: 34193107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
    Aseyev O; Ribeiro JM; Cardoso F
    Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
    Donoghue M; Lemery SJ; Yuan W; He K; Sridhara R; Shord S; Zhao H; Marathe A; Kotch L; Jee J; Wang Y; Zhou L; Adams WM; Jarral V; Pilaro A; Lostritto R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2012 Mar; 18(6):1496-505. PubMed ID: 22282463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.
    Twelves C; Awada A; Cortes J; Yelle L; Velikova G; Olivo MS; Song J; Dutcus CE; Kaufman PA
    Breast Cancer (Auckl); 2016; 10():77-84. PubMed ID: 27398025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
    Dybdal-Hargreaves NF; Risinger AL; Mooberry SL
    Clin Cancer Res; 2015 Jun; 21(11):2445-52. PubMed ID: 25838395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
    Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Eribulin in the treatment for metastatic breast cancer].
    Manzyuk LV; Kovalenko EI; Artamonova E
    Vopr Onkol; 2015; 61(2):195-8. PubMed ID: 26087597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
    Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
    Cortes J; Hudgens S; Twelves C; Perez EA; Awada A; Yelle L; McCutcheon S; Kaufman PA; Forsythe A; Velikova G
    Breast Cancer Res Treat; 2015 Dec; 154(3):509-20. PubMed ID: 26567010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
    Twelves C; Cortes J; Kaufman PA; Yelle L; Awada A; Binder TA; Olivo M; Song J; O'Shaughnessy JA; Jove M; Perez EA
    Breast Cancer Res; 2015 Dec; 17(1):150. PubMed ID: 27391598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
    Tolaney SM; Barroso-Sousa R; Keenan T; Li T; Trippa L; Vaz-Luis I; Wulf G; Spring L; Sinclair NF; Andrews C; Pittenger J; Richardson ET; Dillon D; Lin NU; Overmoyer B; Partridge AH; Van Allen E; Mittendorf EA; Winer EP; Krop IE
    JAMA Oncol; 2020 Oct; 6(10):1598-1605. PubMed ID: 32880602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
    Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
    Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
    Pivot X; Im SA; Guo M; Marmé F
    Breast Cancer; 2018 May; 25(3):370-374. PubMed ID: 29302858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.
    Saji S
    BioDrugs; 2013 Oct; 27(5):469-78. PubMed ID: 23658121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
    Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
    Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
    Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
    Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eribulin.
    Perry CM
    Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.